Latest Essex Woodlands Health Ventures Stories
IRVINE, Calif., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that Guido Neels, Managing Director at Essex Woodlands Health Ventures, has joined the Endologix Board of Directors.
IRVINE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Endologix, Inc.
SAN DIEGO, March 9 /PRNewswire/ -- Victory Pharma, Inc. ("Victory" or "the Company"), a privately held specialty pharmaceutical company, today announced that it has closed on a $45 million equity financing facility led by Essex Woodlands Health Ventures ("Essex").
SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, has raised $40.4 million in a Series C financing round.
MENLO PARK, Calif., Sept. 26 /PRNewswire/ -- Corium International, Inc., a privately-held transdermal drug delivery company, today announced that it has completed a $25.1 million Series C financing led by Essex Woodlands Health Ventures.
- A political dynamiter.